Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.

Although micafungin pharmacokinetic values were comparable between younger (<5 years) and older children (≥5 years) with candidemia and invasive candidiasis, younger children had a lower peak plasma micafungin concentration, lower micafungin exposure and larger micafungin clearance. Half-life remained unchanged with repeated dosing. Metabolite plasma concentrations remained low in older children; however, metabolite M-5 concentrations were higher in younger children.